Episode Synopsis "N-acetyllactosamine (lacNAC) reverts human TIL anergy ex vivo."

Hello In this edition of the podcast I will discuss a paper published by Demotte and collaborators published this year in the journal Immunity "Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes" vol 28, pag 414 of April 2008. In this paper the authors show that LacNAC can compete for galectin-3 binding freeing TCR from TIL to colocalize with CD8 and allow the recovery of efector functional on ex vivo freshly isolated TIL from ovarian cancer and gastric cancer. See you next time.

Listen "N-acetyllactosamine (lacNAC) reverts human TIL anergy ex vivo."

More episodes of the podcast Tumor Immunology Round Table

• How Alum adjuvant boost antigenic response
• Efective anti-cancer immunotherapy with CD4 T cell clone
• Anti-tumor role of {gamma}{delta} T cells in expontaneous prostate tumors
• NKG2D mediated tumor immunity
• N-acetyllactosamine (lacNAC) reverts human TIL anergy ex vivo.
• A diversified memory repertoire from a single naive T cell
• Immune pressure results in mutation of DRIP derived epitope in SIV
• Immune pressure results in mutation of DRIP derived epitope in SIV